We are writing to let you know about an exciting newly funded NIH study at USC.
This new trial, called Advancing Postmenopausal Preventive Therapy (APPT), is designed to study the effects of an estrogen hormone therapy that does not contain progestogen (provera, progesterone) on hardening of the arteries (atherosclerosis) and mental functioning (cognition).
The medication we are studying is called Bazedoxifene/conjugated estrogen (BZA/CE). BZA/CE is an FDA-approved medication designed to deliver estrogen without a progestogen for postmenopausal women with a uterus.
If you are a woman between 45-59 years of age, are within 6 years of menopause, have not had a hysterectomy and do not have heart disease or diabetes, you could qualify for APPT.
For further details, please see the attached brochure, visit our web site at http://aru.usc.edu/ or call us at 323-442-2257.
If you do not qualify for APPT, we would be most appreciative if you would pass this information to someone who may be interested.
Thank you in advance for your help and contribution to medical science.
Howard N. Hodis, M.D.
Harry J. Bauer and Dorothy Bauer Rawlins Professor of Cardiology
Professor of Medicine and Preventive Medicine
Professor of Molecular Pharmacology and Toxicology
Director, Atherosclerosis Research Unit